Martin Wax

Martin B. Wax, M.D., is chief medical officer and executive vice president of R&D at PanOptica, Inc., a private biotechnology company specializing in ophthalmic pharmaceuticals.

He previously served as vice president of R&D and head of discovery research and preclinical sciences at Alcon Laboratories, where he was responsible for the creation and early development of the Alcon pharmaceutical portfolio.

Dr. Wax received his medical degree from the University of Southern California in Los Angeles. He completed his residency in Ophthalmology at Wills Eye Hospital in Pennsylvania, and post-doctoral fellowships in molecular pharmacology and glaucoma at the University of Pennsylvania School of Medicine.

He currently holds an appointment as a Professor of Ophthalmology and Visual Sciences at the University of Texas Southwestern Medical School in Dallas, and has been selected as one of the “Best Doctors in America” by his peers. An internationally recognized scientific expert in the field of glaucoma, Dr. Wax has co-authored more than 200 publications and serves on several scientific advisory committees and editorial boards.

Martin Wax is the CMO , EVP R&D at PanOptica, based in New York, New York, United States, North America. With a background in Biotechnology, Martin Wax has a rich history of leadership and innovation.Martin Wax studied Graduate Medical at University of Southern California. Explore their detailed professional journey, key connections, and contributions to the industry on our platform.